BioSig Technologies Inc (NASDAQ:BSGM) announced Thursday that it has completed the installation of its PURE EP System at the Deborah Heart and Lung Center in Browns Mills, New Jersey.
In a statement, the company said its PURE EP System is also undergoing an evaluation and clinical data collection at the center, under the leadership of Dr Raffaele Corbisiero.
“As an innovative and rapidly growing company, we are excited to have physicians at Deborah not only utilize our technology but also contribute to its advancement. Given COVID-19’s detrimental effects on cardiovascular health, this relationship cannot come at a more important time,” said CEO Kenneth Londoner.
READ: BioSig Technologies issues October 2020 Letter to Shareholders providing highlights on the company’s recent developments and updates
Dr Corbisiero added: “Intracardiac signals are the foundation of everything we do in EP, but we can't treat what we don't see. I am impressed by our early experience with PURE EP showing more of the cardiac signals we want to see."
BioSig said it is currently conducting patient cases under the clinical trial titled “Novel Cardiac Signal Processing System for Electrophysiology Procedures (PURE EP 2.0 Study)” at Texas Cardiac Arrhythmia Research Foundation in Austin, Texas and Mayo Clinic Florida Campus in Jacksonville.
The company also recently added Massachusetts General Hospital and the Hospital of the University of Pennsylvania to its clinical sites.
Contact the author: [email protected]
Follow him on Twitter @PatrickMGraham